



PRESS RELEASE

BSE: 506690	NSE: UNICHEMLAB	Reuters: UNLB.BO	Bloomberg: UN@IN
-------------	-----------------	------------------	------------------

Mumbai, September 23, 2010

Unichem Laboratories receives CEP for Alfuzosin Hydrochloride

Unichem Laboratories Limited has been granted Certificate of suitability to European Pharmacopoeia (CEP) by European Directorate for the Quality of Medicines and Healthcare (EDQM) for Alfuzosin Hydrochloride.

The European Directorate for the Quality of Medicines & HealthCare is a Directorate of the Council of Europe located in Strasbourg. EDQM issues COS for APIs manufacturers to assure the APIs quality imported to EU. EDQM establishes and provides users with official standards for the manufacture and quality control of medicines applicable in all the signatory states of the Convention for the elaboration of a European Pharmacopoeia. It is responsible for setting up privileged collaboration with observer states at the European Pharmacopoeia Commission, and organizing a network of Official Medicines Control Laboratories to collaborate and share expertise.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com.

Contacts:

Mr. M Gundu Rao

Tel: +912266888380

Cell: +919820228944

✉: gundurao@unichemlabs.com

Mr. Rakesh Parikh

Tel: +912266888414

Cell: +919892925555

✉: rparikh@unichemlabs.com

Mr. K Subharaman

Tel: +912266888404

Cell: +919833031121

✉: subharamank@unichemlabs.com

This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

-o0o-